Address: (Linghao Road) No.2 Street, No.20 Economic Development Zone, Hangzhou
LONGTY™ DRUG-COATED PTCA BALLOON CATHETER PRODUCT DETAILS Our PTCA Catheter is explained as a double Lumen coronary Catheter for a rapid exchange with a balloon that can be enlarged and two radiolucent targets (proximal and distal), to facilitate the balloon positioning under X-Ray fluoroscopy.......Send Inquiry
LONGTY™ DRUG-COATED PTCA BALLOON CATHETER
Our PTCA Catheter is explained as a double Lumen coronary Catheter for a rapid exchange with a balloon that can be enlarged and two radiolucent targets (proximal and distal), to facilitate the balloon positioning under X-Ray fluoroscopy. The PTCA Catheter is coated with Paclitaxel pharmaceutical active ingredients (3µg/mm²)
Outstanding performance for kissing balloon under 6F guiding catheter.
Patented hydrophilic coating on distal shaft, and combined with Hypotube proximal shaft, provide outstanding deliverability.
Three-directional memory folding of the balloon allows of size minimization with great withdrawal capability, and ensures the good performance of repeated dilatation.
Soft tapered tip provides smooth transition from guidewire to balloon catheter to avoid "fish mouth", and minimize the vessel damage.
Short shoulder design at both ends of the balloon ensures the precise dilatation, and reduces the damage to normal vessel next to the lesion.
Drug Component Description
The LONGTY™ drug coating on the balloon of the Admiral DCB consists of the drug paclitaxel and the excipient urea. The balloon surface has a nominal paclitaxel dose density of 3.5μg/mm2.
The active pharmaceutical ingredient in the Admiral DCB is paclitaxel. The principal mechanism by which paclitaxel inhibits neointimal growth is through the stabilization of microtubules by preventing their depolymerization during the final G2/M phase of cell division. The CAS Registry number of paclitaxel is 33069-62-4.
The chemical name of paclitaxel is: Benzenepropanoic acid.
Paclitaxel prevents restenosis by blocking proper microtubal formation, thus it inhibits cell division and migration. It inhibits inflammatory processes. After balloon dilatation, injuries to the arterial wall stimulate inflammatory reaction, and the excretion of growth factors occurs as an important process along with the onset of cell division and the migration of smooth muscle cells. Paclitaxel inhibits platelet derived growth factor (PDGF) mediated vascular smooth muscle cell migration to the intima. Paclitaxel also inhibits extracellular matrix secretion and breakdown.
Safety and performance
-Enhanced Coating Integrity
Designed to improve coating durability and drug transfer efficacy, allowing for a lower dosage of Paclitaxel
-Optimized Drug Transfer
Balanced hydrophobic and hydrophilic properties allow efficient drug transfer to the vessel wall
-Minimized Systemic Loss
Less particulates and systemic loss while optimizing arterial tissue Paclitaxel levels.
Previous: No Information